Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + IL-2 in Relapsed/Refractory NHL
NCT00059904Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2003
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, aldesleukin in non-Hodgkin lymphoma (NHL), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2003; status: completed.
02
Drugs
rituximabaldesleukin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00059904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00059904.